0001127602-24-004438.txt : 20240212 0001127602-24-004438.hdr.sgml : 20240212 20240212160349 ACCESSION NUMBER: 0001127602-24-004438 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240209 FILED AS OF DATE: 20240212 DATE AS OF CHANGE: 20240212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Li Dean Y CENTRAL INDEX KEY: 0001837016 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 24619827 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2024-02-09 0000310158 Merck & Co., Inc. MRK 0001837016 Li Dean Y MERCK & CO., INC. 126 EAST LINCOLN AVENUE RAHWAY NJ 07065 1 Executive VP & President, MRL 0 Common Stock 2024-02-09 4 M 0 14702 62.07 A 60944.37 D Common Stock 2024-02-09 4 S 0 14702 125.4988 D 46242.37 D Stock Option (Right to Buy) 62.07 2024-02-09 4 M 0 14702 0 D 2018-05-05 2027-05-04 Common Stock 14702 0 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.4900 to $125.5330, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Holdings include shares acquired in dividend reinvestment transactions. Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. /s/ Kelly E. W. Grez as Attorney-in-Fact for Dean Y. Li 2024-02-12